Gedatolisib combinations significantly extend progression-free survival after CDK4/6 inhibitor failure in HR+/HER2– breast cancer, with manageable adverse effects and stable quality of life.
Sara A. Hurvitz, MD
Advertisement
Articles by Sara A. Hurvitz, MD
122 Adjuvant Ribociclib (RIB) Plus Nonsteroidal Aromatase Inhibitor (NSAI) in Patients With HR+/HER2− Early Breast Cancer (EBC): NATALEE 5-Year Outcomes
ByJohn Crown,Daniil Stroyakovskii,Denise A. Yardley, MD,Chiun-Sheng Huang,Peter A. Fasching,Aditya Bardia, MD, MPH, FASCO,Stephen Chia,Seock-Ah Im,Miguel Martin, MD, PhD,Binghe Xu,Carlos H Barrios,Michael Untch, MD, PhD,Rebecca Moroose,Sara A. Hurvitz, MD,Gabriel N. Hortobagyi, MD, FACP,Dennis J. Slamon, MD, PhD,Frances Visco,Gonzalo Spera,Zheng Li,Sherene Loi, MD, PhD
131 Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-[L]1i)
ByJavier Cortés, MD,Aditya Bardia, MD, MPH, FASCO,Kevin Punie,Carlos Barrios,Sara A. Hurvitz, MD,Andreas Schneeweiss, MD,Joohyuk Sohn,Eriko Tokunaga,Adam M. Brufsky, MD, PhD,Yeon Hee Park,Binghe Xu,Roberto Hegg,Mafalda Oliveira,Alessandra Fabi,Natalya Vaksman,Theresa Valdez,Xinrui Zhang,Catherine Lai, MD, MPH,Sara M. Tolaney, MD, MPH
Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial
ByGabriel N. Hortobagyi, MD, FACP,Daniil Stroyakovskiy,Denise A. Yardley, MD,Chiun-Sheng Huang,Peter A. Fasching,John Crown,Aditya Bardia, MD, MPH, FASCO,Stephen Chia,Seock-Ah Im,Miguel Martin, MD, PhD,Sherene Loi, MD, PhD,Binghe Xu,Sara A. Hurvitz, MD,Carlos Barrios,Michael Untch, MD, PhD,Rebecca Moroose,Frances Visco,Federico Parnizari,Farhat Ghaznawi,Zheng Li,Sorcha Waters,Arunava Chakravartty,Dennis J. Slamon, MD, PhD
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer
ByMatthew P. Goetz, MD,Masakazu Toi,Jens Huober, MD,Joohyuk Sohn,Oliver Trédan,In Hae Park,Mario Campone,Shin-Cheh Chen,Luis Manuel Manso,Shani Paluch-Shimon,Orit C. Freedman,Joyce A. O’Shaughnessy,Xavier Pivot,Sara M. Tolaney, MD, MPH,Sara A. Hurvitz, MD,Antonio Llombart,Valérie André,Abhijoy Saha,Gertjan van Hal,Ashwin Shahir,Hiroji Iwata,Stephen R.D. Johnston
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Adding trastuzumab emtansine to tucatinib appears to significantly improve progression-free survival in patients with metastatic HER2-positive breast cancer, says Sara Hurvitz, MD, FACP.
24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study
BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Erika P. Hamilton, MD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath Jeselsohn,Pamela N. Munster, MD,Haolan Lu,Richard Gedrich,Cecile Mather,Janaki Parameswaran,Hyo S Han
Sara Hurvitz, MD, spoke about ongoing clinical trials in which trastuzumab deruxtecan is being investigated with the use of brain metastases.
Sara Hurvitz, MD, spoke which patients would benefit most from fam-trastuzumab deruxtecan and what the next research steps will be.
Sara Hurvitz, MD, spoke to the difficulty of treating HER2-positive and advanced HER2-positive breast cancer and how the efficacy of novel agents such as fam-trastuzumab deruxtecan-nxki could make a difference in treating the disease.
Sara Hurvitz, MD, spoke about to recent approval of fam-trastuzumab deruxtecan-nxki in the second-line setting for patients with HER2-positive breast cancer.
A neuro-oncologist explains the prevalence of leptomeningeal metastases in HER2+ breast cancer and her preferred method of treatment.
A multidisciplinary panel of health care professionals and a patient advocate comment on their excitement about novel therapies in the pipeline for HER2-positive metastatic breast cancer.
Improvements regarding the identification and management of radiation necrosis in patients with HER2-positive metastatic breast cancer.
The importance of forming partnerships with patients and understanding their preferences for therapy when establishing treatment algorithms for patients with HER2-positive metastatic breast cancer.
Sara A. Hurvitz, MD, and Julia A. LaBarbera, NP, of UCLA, highlight the safety and efficacy profiles of newer novel treatment options available for HER2-positive breast cancer and brain metastases.
Variables that impact decisions to treat HER2-positive breast cancer and brain metastases with radiation therapy and systemic therapy, and recommendations on using memantine following radiation therapy.
Treatment recommendations for patients with HER2-positive metastatic breast cancer, like Erika Rich, upon identification of lesions in the brain.
Advertisement
Latest Updated Articles
Novel Agents in Early Trials for Breast CancerJuly 11th 2012
Advertisement
Advertisement
Trending on CancerNetwork
1
Melanoma Trials You May Have Missed at ASCO 2026
2
Investigators Halt Phase 3 Trial of Sacituzumab Govitecan Combo in NSCLC
3
Subcutaneous Isatuximab Earns EU Approval in Multiple Myeloma
4
Daraxonrasib/Vopimetostat Yield Stunning Response Rate in MTAP-del Pancreatic Cancer
5